S&P 500   4,239.89 (-1.02%)
DOW   33,814.30 (-0.54%)
QQQ   323.64 (-1.71%)
AAPL   172.78 (-0.79%)
MSFT   286.80 (-1.16%)
META   168.10 (-3.76%)
GOOGL   117.62 (-2.12%)
AMZN   138.70 (-2.53%)
TSLA   887.32 (-2.34%)
NVDA   179.53 (-4.37%)
NIO   19.07 (-4.22%)
BABA   89.42 (-1.45%)
AMD   95.66 (-4.76%)
T   18.39 (-0.22%)
MU   60.89 (-3.32%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.61 (-2.02%)
DIS   120.45 (-1.81%)
AMC   18.17 (-5.81%)
PYPL   97.45 (-2.41%)
PFE   49.34 (+1.56%)
NFLX   238.22 (-2.83%)
S&P 500   4,239.89 (-1.02%)
DOW   33,814.30 (-0.54%)
QQQ   323.64 (-1.71%)
AAPL   172.78 (-0.79%)
MSFT   286.80 (-1.16%)
META   168.10 (-3.76%)
GOOGL   117.62 (-2.12%)
AMZN   138.70 (-2.53%)
TSLA   887.32 (-2.34%)
NVDA   179.53 (-4.37%)
NIO   19.07 (-4.22%)
BABA   89.42 (-1.45%)
AMD   95.66 (-4.76%)
T   18.39 (-0.22%)
MU   60.89 (-3.32%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.61 (-2.02%)
DIS   120.45 (-1.81%)
AMC   18.17 (-5.81%)
PYPL   97.45 (-2.41%)
PFE   49.34 (+1.56%)
NFLX   238.22 (-2.83%)
S&P 500   4,239.89 (-1.02%)
DOW   33,814.30 (-0.54%)
QQQ   323.64 (-1.71%)
AAPL   172.78 (-0.79%)
MSFT   286.80 (-1.16%)
META   168.10 (-3.76%)
GOOGL   117.62 (-2.12%)
AMZN   138.70 (-2.53%)
TSLA   887.32 (-2.34%)
NVDA   179.53 (-4.37%)
NIO   19.07 (-4.22%)
BABA   89.42 (-1.45%)
AMD   95.66 (-4.76%)
T   18.39 (-0.22%)
MU   60.89 (-3.32%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.61 (-2.02%)
DIS   120.45 (-1.81%)
AMC   18.17 (-5.81%)
PYPL   97.45 (-2.41%)
PFE   49.34 (+1.56%)
NFLX   238.22 (-2.83%)
S&P 500   4,239.89 (-1.02%)
DOW   33,814.30 (-0.54%)
QQQ   323.64 (-1.71%)
AAPL   172.78 (-0.79%)
MSFT   286.80 (-1.16%)
META   168.10 (-3.76%)
GOOGL   117.62 (-2.12%)
AMZN   138.70 (-2.53%)
TSLA   887.32 (-2.34%)
NVDA   179.53 (-4.37%)
NIO   19.07 (-4.22%)
BABA   89.42 (-1.45%)
AMD   95.66 (-4.76%)
T   18.39 (-0.22%)
MU   60.89 (-3.32%)
CGC   3.83 (+0.52%)
F   15.88 (-1.67%)
GE   77.61 (-2.02%)
DIS   120.45 (-1.81%)
AMC   18.17 (-5.81%)
PYPL   97.45 (-2.41%)
PFE   49.34 (+1.56%)
NFLX   238.22 (-2.83%)
NASDAQ:ZYNE

Zynerba Pharmaceuticals - ZYNE Stock Forecast, Price & News

$1.20
-0.10 (-7.69%)
(As of 08/19/2022 12:31 PM ET)
Add
Compare
Today's Range
$1.19
▼
$1.26
50-Day Range
$1.01
▼
$1.36
52-Week Range
$0.84
▼
$4.65
Volume
5,434 shs
Average Volume
552,932 shs
Market Capitalization
$54.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.33

Zynerba Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
733.3% Upside
$10.33 Price Target
Short Interest
Healthy
1.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Zynerba Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$33,571 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.93) to ($0.83) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

581st out of 1,119 stocks

Pharmaceutical Preparations Industry

285th out of 549 stocks

See Top Rated MarketRank™ Stocks Here
ZYNE stock logo

About Zynerba Pharmaceuticals (NASDAQ:ZYNE) Stock

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. StockNews.com upgraded shares of Zynerba Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday, May 27th. Canaccord Genuity Group restated a "buy" rating and issued a $11.00 target price (up previously from $9.00) on shares of Zynerba Pharmaceuticals in a research report on Thursday, June 23rd. Finally, Canaccord Genuity Group upped their target price on shares of Zynerba Pharmaceuticals from $9.00 to $11.00 and gave the stock a "buy" rating in a research report on Thursday, June 23rd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Zynerba Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $10.33.

Zynerba Pharmaceuticals Stock Performance

ZYNE opened at $1.30 on Friday. Zynerba Pharmaceuticals has a one year low of $0.84 and a one year high of $4.65. The stock's fifty day moving average is $1.18 and its 200-day moving average is $1.56. The company has a market capitalization of $59.48 million, a PE ratio of -1.40 and a beta of 1.86.

Zynerba Pharmaceuticals (NASDAQ:ZYNE - Get Rating) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01. On average, equities research analysts forecast that Zynerba Pharmaceuticals will post -0.93 EPS for the current fiscal year.

Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZYNE Stock News Headlines

August 17, 2022 | nasdaq.com
We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
August 16, 2022 | seekingalpha.com
Zynerba Pharmaceuticals (ZYNE) Investor Presentation - Slideshow
August 16, 2022 | americanbankingnews.com
Brokers Issue Forecasts for Zynerba Pharmaceuticals, Inc.'s Q3 2022 Earnings (NASDAQ:ZYNE)
August 11, 2022 | proactiveinvestors.com
Zynerba Pharmaceuticals gets renewed 'Buy' rating, premium $11 price target from Canaccord Genuity after growth conference
August 10, 2022 | msn.com
Zynerba Pharmaceuticals R&D Expanses For Q2 Reach 5.4M, Here Are The Details
August 10, 2022 | proactiveinvestors.com
Zynerba Pharmaceuticals reports Q2 results and provides operational update
August 10, 2022 | nz.finance.yahoo.com
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
August 5, 2022 | americanbankingnews.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Share Price Crosses Above Fifty Day Moving Average of $1.12
August 3, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference
August 1, 2022 | finance.yahoo.com
We're Hopeful That Zynerba Pharmaceuticals (NASDAQ:ZYNE) Will Use Its Cash Wisely
July 21, 2022 | proactiveinvestors.com
Zynerba Pharmaceuticals increases financial flexibility with $20M equity purchase agreement
July 21, 2022 | proactiveinvestors.com
Zynerba Pharmaceuticals enters into equity purchase agreement for up to $20M with Lincoln Park Capital
July 21, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
July 21, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
July 7, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference
June 24, 2022 | finance.yahoo.com
Lab Notes: AmerisourceBergen aims to help cell and gene therapy developers, Penn spinout expands research deal with university
June 22, 2022 | finance.yahoo.com
Zynerba's Cannabidiol Formulated Gel Shows Encouraging Action In Genetic Disease
June 22, 2022 | benzinga.com
Zynerba Pharmaceuticals Reveals Positive Results From Phase 2 INSPIRE Trial Of Zygel In 22q11.2 Deletion Syndrome
June 22, 2022 | seekingalpha.com
Zynerba stock rises as CBD gel improves rare disorder symptoms in trial; autism program deferred
June 22, 2022 | ca.proactiveinvestors.com
Zynerba Pharmaceuticals reports positive results from Phase 2 trial of Zygel CBD gel in 22q11.2 Deletion Syndrome
June 21, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome
June 1, 2022 | ca.proactiveinvestors.com
Zynerba Pharmaceuticals presents data on Zygel CBD gel at American Society of Clinical Psychopharmacology event this week
June 1, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting
May 24, 2022 | finance.yahoo.com
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
May 16, 2022 | benzinga.com
Recap: Zynerba Pharmaceuticals Q1 Earnings
See More Headlines
Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZYNE Company Calendar

Last Earnings
11/15/2021
Today
8/19/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZYNE
CUSIP
N/A
CIK
1621443
Web
www.zynerba.com
Phone
(484) 581-7505
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.33
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+761.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.93)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,310,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-55.50%
Return on Assets
-48.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.89
Quick Ratio
6.89

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.25 per share
Price / Book
0.96

Miscellaneous

Outstanding Shares
45,750,000
Free Float
40,931,000
Market Cap
$54.90 million
Optionable
Optionable
Beta
1.86

Key Executives

  • Mr. Armando Anido MBA (Age 64)
    Chairman & CEO
    Comp: $993.36k
  • Ms. Terri B. Sebree (Age 64)
    Pres
    Comp: $764.03k
  • Mr. James E. Fickenscher (Age 58)
    CFO & VP of Corp. Devel.
    Comp: $608.02k
  • Mr. Albert P. Parker II (Age 56)
    Chief Legal Officer & Corp. Sec.
  • Mr. Joseph Apostolico
    VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ZYNE Stock - Frequently Asked Questions

Should I buy or sell Zynerba Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZYNE shares.
View ZYNE analyst ratings or view top-rated stocks.

What is Zynerba Pharmaceuticals' stock price forecast for 2022?

4 Wall Street analysts have issued 1 year target prices for Zynerba Pharmaceuticals' shares. Their ZYNE share price forecasts range from $9.00 to $11.00. On average, they expect the company's stock price to reach $10.33 in the next year. This suggests a possible upside of 694.9% from the stock's current price.
View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts.

How have ZYNE shares performed in 2022?

Zynerba Pharmaceuticals' stock was trading at $2.88 at the beginning of the year. Since then, ZYNE shares have decreased by 54.9% and is now trading at $1.30.
View the best growth stocks for 2022 here.

When is Zynerba Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our ZYNE earnings forecast.

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.01.

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (2.83%), Renaissance Technologies LLC (1.69%), Millennium Management LLC (0.70%), IQ EQ FUND MANAGEMENT IRELAND Ltd (0.51%), Cetera Advisor Networks LLC (0.06%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Armando Anido, Brian Rosenberger, Daniel L Kisner, James E Fickenscher and Terri B Sebree.
View institutional ownership trends.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $1.30.

How much money does Zynerba Pharmaceuticals make?

Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a market capitalization of $59.48 million. The company earns $-37,310,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The official website for the company is www.zynerba.com. The company can be reached via phone at (484) 581-7505 or via email at investorrelations@zynerba.com.

This page (NASDAQ:ZYNE) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.